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Abstract 
Interallelic interactions of membrane proteins are not taken into account while evaluating the 
pathogenicity of sequence variants in autosomal recessive disorders. Podocin, a membrane-anchored 
component of the slit diaphragm, is encoded by NPHS2, the major gene mutated in hereditary 
podocytopathies. We formerly showed that its R229Q variant is only pathogenic when trans-
associated to specific 3’ mutations and suggested the causal role of an abnormal C-terminal 
dimerization. Here we show by FRET analysis and size exclusion chromatography that podocin 
oligomerization occurs exclusively through the C-terminal tail (residues 283-382): principally through 
the first C-terminal helical region (H1, 283-313), which forms a coiled coil as shown by circular 
dichroism spectroscopy, and through the 332-348 region. We show the principal role of the 
oligomerization sites in mediating interallelic interactions: while the monomer-forming R286Tfs*17 
podocin remains membranous irrespective of the coexpressed podocin variant identity, podocin 
variants with an intact H1 significantly influence each other’s localization (r2=0.68, P = 9.2 x 10-32). 
The dominant negative effect resulting in intracellular retention of the pathogenic F344Lfs*4-R229Q 
heterooligomer occurs in parallel with a reduction in the FRET efficiency, suggesting the causal role 
of a conformational rearrangement. On the other hand, oligomerization can also promote the 
membrane localization: it can prevent the endocytosis of F344Lfs*4 or F344* podocin mutants 
induced by C-terminal truncation. In conclusion, C-terminal oligomerization of podocin can mediate 
both a dominant negative effect and interallelic complementation. Interallelic interactions of NPHS2 
are not restricted to the R229Q variant and have to be considered in compound heterozygous 
individuals. 
 
keywords: dominant negative effect, complementation, podocin, nephrotic syndrome, endocytosis, 
membrane targeting 
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Introduction 
Podocin, named after its podocyte-specific expression, is a member of the stomatin protein family. It 
is encoded by NPHS2, mutations of which are a frequent cause of autosomal recessive steroid-
resistant nephrotic syndrome (SRNS) being responsible for 15-39% of congenital and infantile and 13-
14% of childhood SRNS.1-5 Podocin is a 42 kDa integral membrane protein, localized exclusively in the 
slit diaphragm,6 with both N- and C-termini facing the cytosolic side.7 It is associated to lipid rafts 
where it recruits nephrin through its PHB domain,6,8,9 thereby augmenting the nephrin-induced 
activation of the AP-1 transcription factor.9 In addition, podocin interacts with CD2-associated 
protein6, CIN8510, NOX211 and the transient receptor potential C channel protein TRPC6.12,13 Podocin 
was found to assemble the NOX2 and TRPC6 complex and thus to allow the gating of TRPC6 by 
reactive oxygen species.11 Nevertheless, the function of podocin is not entirely understood. It is 
known to form oligomers,6 and all the N- and C-terminal parts and the central PHB domain were 
shown to homodimerize suggesting that the oligomerization may occur through any of these 
domains.8 
The most frequent missense variant of NPHS2, R229Q (rs61747728, MAF: 3,75% in Europeans14) was 
formerly found enriched in patients with late-onset focal segmental glomerulosclerosis (FSGS) 15 and 
to predispose in familial hematuria for high-degree proteinuria16,17. We formerly showed that R229Q 
does not cause FSGS in the homozygous state18, but only when trans-associated to specific 
mutations, providing the first example of a clinically determinant interallelic interaction in an 
autosomal recessive disorder.19 We found the R229Q podocin to be retained in cytoplasmic 
compartments by some specific C-terminal missense mutants, as A284V, A288T, R291W, A297V and 
E310K. We calculated, based on molecular modeling studies, that the R229Q makes the C-terminal 
helical tail less flexible, which makes it prone to form abnormal heterodimers with these latter 
podocin mutants also affecting the dimerization. Thus, a potential explanation for the dominant 
negative effect of these mutants was an altered conformation of their heterodimers with R229Q 
podocin.19 
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Recently, the 3’ frameshift mutation (c.1032delT, p.F344Lfs*4) was also reported to be associated to 
R229Q in several Kashubian families with SRNS, suggesting it to be the first frameshift mutation 
pathogenic with R229Q.20 This prompted us to identify the oligomerization sites of podocin and to 
investigate how 3’ truncating mutations affect the binding capacity and the localization of podocin.  
Here we show that oligomerization of podocin occurs exclusively through the C-terminal tail (CTT), 
and influences the localization of podocin in a complex fashion, mediating either a dominant 
negative effect or even interallelic complementation. 
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Results 
The C-terminal tail of podocin folds into three helices 
The C-terminal part of podocin (residues 124-383) contains a PHB domain (124-282) and a long tail 
region (CTT, 283-383), the end section of which (distal to N355) is disordered.21 Three helices are 
predicted in the CTT (H1-H3) (Fig. 1b).22 The structure of H1 and H2 were confirmed to be helical both 
by the crystal structure of stomatin,23 which shares a homology of 69% in this region with podocin 
(Fig. 1a,b) and by our previous molecular dynamics simulations.19 The TVV motif – located in the H2-
H3 linker and shown to mediate internalization24 – is predicted to form a short -strand (Fig. 1b). In 
order to assess the role of these regions in the dimerization, we studied the dimerization of three 
frequent C-terminal frameshift mutants, the R286Tfs*17, the A317Lfs*31, the F344Lfs*4 podocin and 
a laboratory-derived mutant, the F344* podocin. They all lead to premature stop in the last exon, but 
they differ in the modular build-up of their CTT domain: while all helical domains are disrupted in the 
R286Tfs*17 podocin, the H1 remains intact in the A317Lfs*31 podocin, and the F344Lfs*4 or the 
F344* podocin possesses intact H1, H2 and TVV motifs (Fig. 1c). 
 
Podocin oligomerization occurs exclusively through the CTT 
We found an approximately 20% FRET efficiency in the wt and the R229Q homooligomers supporting 
the formation of strong associations (Fig. 1d,e). In contrast, the FRET efficiency measured between 
R286Tfs*17 podocin and either the wt or R229Q podocin did not exceed that of the negative control 
indicating that podocin is unable to dimerize if all three C-terminal helical regions are disrupted (Fig. 
1d,e). These results show the exclusive role of the CTT in the oligomerization. The R229Q, 
A317Lfs*31, F344* or F344Lfs*4 variants markedly influenced the FRET efficiency (Fig. 1d,e), 
indicating the significant effect of R229Q and the three helical regions on the oligomer conformation. 
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Figure 1. Podocin dimerizes through the C-terminal tail 
a-b) Secondary structure prediction for the C-terminal fragment of stomatin (a) and podocin (b). Wild 
type C-terminal residues from E210 of stomatin and E264 of podocin are marked according to their 
loop- (blue), strand- (red) or helix-forming (green) propensity.22 Values above five indicate significant 
probabilities. Three helical regions are predicted in both stomatin (H1: 210-244, H2: 245-260, H3: 
273-281) and podocin (H1: 283-313, H2: 317-330 and H3: 344-350). The border between H1 and H2 
of stomatin is predicted based on the crystal structure of Pyrococcus horikoshii stomatin.23  
c) Sequence of the studied truncated podocin mutants. The altered sequences following the 
frameshift sites are framed. 
d-e) Förster resonance energy transfer (FRET) efficiency in the oligomers of wt (d) or R229Q podocin 
(e) and the truncated podocin variants. Wt (d) and R229Q podocin (e) are labeled with the donor 
dye, the second component by the acceptor dye. As compared with the F344* oligomers, the FRET 
efficiency increased in the non-pathogenic F344Lfs*4-wt oligomer (P = 0.0003) and decreased in the 
pathogenic F344Lfs*4-R229Q oligomer (P = 0.024), showing a different effect of the FDL344_346LTY 
substitutions on their conformation. 
*P  0.0003 as compared with the wt-negative control, #P  0.006 as compared with the wt-wt 
homodimer, †P = 0.0002 as compared with the R229Q-negative control, §P  0.0003 as compared 
with the R229Q-wt dimer, neg.: negative 
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Podocin oligomerizes through the 273-313 and the 332-348 residues 
We subsequently aimed to determine the oligomerization sites of podocin within the CTT, studying 
homooligomers of C-terminal podocin segments (R168-) with different CTT truncations (Fig. 2). The 
168-269 fragment – missing the entire CTT – did not form homodimers according to both FRET 
analysis and size exclusion chromatography (Fig. 2a,b). Elongation of the sequence just by 17 or 23 
amino acids (168-286 and 168-292: containing subsections of the H1 helix) resulted in dimer 
formation (Fig. 2a), with a low FRET efficiency (Fig. 2b). In contrast, the 168-R286Tfs*17 fragment 
formed monomers, with low elution volume and no FRET (Fig. 2a,b), similarly to the entire 
R286Tfs*17 podocin (Fig. 1d,e), indicating that its frameshift sequence disrupts the dimerization. The 
FRET efficiency of the segment with a full H1 domain (168-313) was already as high as that of the 
fragment containing all three helical regions (168-348) or the full CTT (168-383), supporting the 
principal role of H1 in the dimerization (Fig. 2b). The 168-331 sequence, containing both H1 and H2, 
also formed dimers (Fig. 2a), but exerted a markedly lower FRET (Fig. 2b). This can be explained by 
our previously built up structural model of the 161-332 podocin homodimer19: the PHB domains 
containing the FRET dye binding sites (Suppl. Fig. 1), are 60 Å apart, near the limit of FRET 
detectability. The higher FRET efficiency of the 168-313 homodimer suggests a slight rotation of the 
interacting helices which create in a 10-15 Å shift of the PHB domains (Fig. 2c). Once the segment 
contained all three CTT helices (168-348 or 168-383), the presence of high order oligomers (Fig. 2a) 
was also detected. These results show that the second oligomerization site is located in the region of 
the 332-348 residues building up the H2-H3 linker and the H3 helix. 
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Figure 2. Oligomerization sites of podocin 
a-b) Homooligomerization capacity of MBP-fused C-terminal podocin fragments assessed by size 
exclusion chromatography (a) and FRET analysis (b). The fragment without the H1 helix (168-269) and 
the fragment corresponding to the R286Tfs*17 mutant (168-286fs) formed monomers according to 
both analyses. Fragments containing at least the first part of H1 (168-286), (168-292), the entire H1 
(168-313) or also the H2 (168-331) formed dimers (a) with a variable FRET efficiency (b). The 
fragment containing also the H2-H3 linker (168-348) and the full CTT formed also oligomers (a) and 
produced highly efficient FRET (b). 
*, **, *** levels of significance as compared with the FRET efficiency of the 168-269 fragment: *P = 
0.034, **P  0.004, ***P = 0.0002, #P = 0.0002 as compared with the FRET efficiency of the full CTT 
(168-383) 
c) Probable arrangements of various podocin fragments in stable homodimers, created based on our 
previously published dimer model. Models are colored according to the chromatograms of a), the 
labeled Cys254 residues are shown in yellow. The Cys254(monomerA)-Cys254(monomerB) 
separation increases due to the partial absence of H1 (in case of R168_R286 and R168_M292) or the 
joint presence of H1 and H2 (R168_S331), compared with a dimer containing only the entire H1 helix 
(R168_S313) with more optimal Cys254(monomerA)-Cys254(monomerB) separation. 
d) Far-UV ECD spectra of the H1 domain (P271_S313) from 5°C to 65°C, showing the presence of an 
-helical structure at low temperatures, which is unfolded by heating. 
e) The ratio of molar ellipticity at 222 and 208 nm of the H1 domain (P271_S313), as a function of the 
temperature between 5°C and 85°C, reflects a coiled-coil association. After cooling, the spectra of an 
-helical coiled coil structure could be recovered. 
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Supplementary Figure 1. Position of the cysteine residues in the 168-348 podocin fragment 
The two cysteine residues in the 168-348 segment, Cys193 and Cys254, are both located in the PHB 
domain. Since the Cys193 points toward the inner core of the domain, the Cys254 residue is the 
expected maleimide binding site. 
  
 
 
 
 
 
 
 
 
 
 
 
The H1 domain forms coiled-coil like associations 
We assessed the structure of the first oligomerization site by measuring its temperature-dependent 
far-UV ECD spectra (Fig. 2d). At 5°C the ECD spectrum displayed a positive maximum near 190 nm 
and two minima at 208 and 222 nm with a 222/208 nm ellipticity ratio characteristic of coiled-coil 
alpha-helices. 25 Above 40°C, the unstructured propensity increased, indicating the emergence of a 
structural ensemble of elevated internal dynamics, with the ellipticity ratio decreasing below 0.7. 
This effect was reversible: the ECD spectrum regained its former characteristics typical of coiled-coil 
alpha-helices after cooling back from 85°C to 5°C. These findings confirm that the first 
oligomerization site reversibly forms coiled-coil like associations (Fig. 2d,e). 
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Effect of C-terminal truncation on the localization 
The C-terminal truncations led to markedly different localization: while we found the R286Tfs*17 
podocin to be as membranous as the wt podocin, the A317Lfs*31 podocin was only partly 
membranous and the F344Lfs*4 and F344* podocin mutants localized in vesicles (Fig. 3a). The 
perfect membranous localization of R286Tfs*17 is in accordance with its hypomorphic nature, as 
patients who are either homozygous for R286Tfs*17 or carry a null mutation in trans, progress to 
ESRD at the median age of 14 years (range: 8-17, n = 13) in the French cohort, i.e. later than patients 
with the A317Lfs*31 mutation (median: 6.2, range: 3.9-11, n = 6, P = 0.02), or compared to patients 
with two null mutations.26  
 
Figure 3. Membrane targeting of podocin variants as a function of the coexpressed podocin variant  
a) Podocytes expressing GFP-tagged wt and missense podocin variants and/or HA-tagged wt and 
truncated podocin variants. The GFP-tagged podocin variants are shown in green, the HA-tagged 
podocin variants are in red. The plasma membrane is labeled with wheat germ agglutinin and shown 
in blue. The R286Tfs*17 podocin is perfectly membranous, does not colocalize with any of the 
coexpressed podocin variants, nor is influenced in its localization by them (c). In contrast, the 
A317Lfs*31 podocin is only partially membranous and the F344* and F344Lfs*4 podocin variants 
localize in vesicles. These three podocin variants colocalize with the coexpressed podocin variants 
and are strongly influenced in their localization by them (c, Suppl. Fig. 2). Interestingly, the F344* and 
F344Lfs*4 podocin mutants become perfectly membranous when associated with membranous 
podocin variants, except for the pathogenic R229Q-F344Lfs*4 association. This latter shows a 
dispersed reticular localization, typical of pathogenic R229Q-associations. Scale bar, 20μm. 
b-c) Membrane targeting of GFP-tagged missense and wt podocin variants (b) and HA-tagged 
truncated and wt podocin variants (c) as a function of the coexpressed podocin variants shown in 
parentheses, quantified in 10 cells per group. P values show the significance of Kruskal-Wallis tests.  
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*, **, *** levels of significance as compared with the membrane localization of the corresponding 
monoexpressed variant: *P  0.05, **P = 0.002, ***P  0.0001 
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Supplementary Figure 2. Correlation in the membrane localization of coexpressed podocin variants 
between variants with (a, c) and without (b, d) dimer-forming capacity. (suppl. to Fig. 3) 
Data are presented either as the values obtained in single cells (a,b) or as a median calculated in each 
group of 10 cells expressing the same podocin pairs, corresponding to Figure 3. While there is a 
strong correlation in the membrane-localization of the coexpressed podocin variants forming 
heterodimers or heterooligomers (a,c), the correlation in the membrane localization of podocin 
variants which do not form heterodimers is weak (b) or absent (d). 
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The F344Lfs*4 and F344* mutations result in internalization of podocin 
The distinct vesicular localization of the F344Lfs*4 and F344* podocin variants suggested their 
internalization, in accordance with former results.24 We found indeed vesicles positive for both 
internalized transferrin and F344Lfs*4 and F344* podocin variants supporting their clathrin-mediated 
endocytosis (Fig. 4a). Furthermore, blocking the dynamin-mediated endocytosis by coexpressing the 
dominant negative mutant (K44A) dynamin,27 made the F344Lfs*4 and F344* podocin variants 
partially membrane-localized (Fig. 4b,c). These results showed that the vesicular localization of the 
F344Lfs*4 and F344* podocin variants is at least partially due to endocytosis (Fig. 5). 
 
Figure 4. The F344Lfs*4 and F344* podocin mutants are internalized 
a) The HA-tagged F344Lfs*4 podocin and the fluorescent transferrin, internalized for 10 minutes, 
colocalize in vesicles of podocytes, suggesting that F344Lfs*4 podocin is endocytosed. Scale bar, 
20μm. 
b) Blockade of endocytosis by the coexpression of dominant negative (K44A) dynamin makes the 
F344Lfs*4 and F344* podocin variants partially membranous. HA-tagged podocin variants or 
transferrin are shown in red, GFP-tagged dynamin in green and WGA or Hoechst in blue. While 
endocytosis was not altered by wt dynamin, it was inhibited by K44A dynamin with a dominant 
negative effect, as demonstrated by the lack of transferrin uptake in the cell expressing K44A 
dynamin. K44A dynamin makes the F344Lfs*4 and F344* podocin variants partially membranous (c), 
indicating that their vesicular localization is explained at least partially by internalization. Scale bar, 
20μm. 
c) Membrane targeting of podocin as a function of the coexpressed dynamin variant, quantified in 
10-12 cells per group. 
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F344Lfs*4 podocin retains R229Q podocin in accordance with their pathogenicity  
We next investigated the localization of R229Q podocin as a function of the coexpressed truncated 
podocin variants. As the allele frequency of R229Q (3.8% in Europe) is 50x higher than the cumulative 
allele frequency of all other pathogenic NPHS2 variants in the European population,14 the 
pathogenicity of its associations with relatively frequent mutations can be judged on an 
epidemiological basis.19 Among the truncating mutations, F344Lfs*4 has been uniquely reported to 
be frequently associated to R229Q in patients,5,20,28 rendering the pathogenicity of their association 
unquestionable. On the other hand, A317Lfs*31 and R286Tfs*17 are unexpected to be pathogenic 
with R229Q, either because they have never been associated to R229Q in affected individuals despite 
their high allele frequency in the patient cohorts (A317Lfs*31) or were associated to R229Q in 
patients with steroid-sensitive nephrotic syndrome (R286Tfs*17) proving the functionality of R229Q 
podocin when coexpressed with R286Tfs*17 podocin.29 Along this line, R229Q podocin lost its 
membrane localization only when coexpressed with F344Lfs*4 (Fig. 3a,b, Fig. 5), with a similar 
dispersed reticular localization to that of the other pathogenic associations of R229Q.19 As the F344* 
podocin did not abolish the membrane localization of R229Q podocin, the dominant negative effect 
of F344Lfs*4 is expected to be exerted by the FDL344_346LTY substitutions and not by the C-
terminal truncation (Fig. 3a,b).  
In accordance with the recessive transmission of NPHS2-associated nephrotic syndrome, the wt 
podocin remained membranous when coexpressed with all four truncated podocin variants, though 
A317Lfs*31 decreased its membrane-targeting in a non-significant, highly variable fashion (Fig. 3a,b). 
Furthermore, unexpectedly, the wt podocin made the coexpressed F344Lfs*4 or F344* podocin 
mutants perfectly membranous, suggesting a complementary effect (Fig. 3a,c, Fig. 5). This prompted 
us to examine the effect of missense podocin mutants on the localization of the truncated podocin 
variants.  
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Missense podocin variants can restore the membrane localization of the truncated forms 
In addition to the wt and R229Q podocin, we coexpressed the R238S and A297V podocin variants 
with the truncated podocin proteins to study their interactions. While the R238S podocin has an 
intact CTT domain and is known to be membranous (Fig. 3a,b),30 the A297V podocin has an altered 
CTT structure 19 and shows a dispersed reticular localization (Fig. 3a,b).  
In accordance with the lack of its dimerization capacity, the R286Tfs* podocin did not colocalize with 
any of the coexpressed podocin variants through their trafficking (Fig. 3a), and the membrane 
localization of R286Tfs* podocin was not influenced by any of them (Fig. 3a,c, Fig. 5, Suppl. Fig. 2). 
The truncated podocin variants with an intact H1 domain (A317Lfs*31, F344Lfs*4 and F344*) 
strongly colocalized with the missense mutants, and their localization was significantly influenced by 
them (Fig. 3a,c, Suppl. Fig. 2). They showed a dispersed reticular localization when coexpressed with 
A297V podocin (Fig. 3a), similar to that of the R229Q-A297V association.19 Thus, A317Lfs*31 podocin 
lost its partial membrane localization with A297V podocin. On the other hand, the R238S podocin, 
similarly to the wt podocin, made the F344Lfs*4 and F344* podocin variants perfectly membranous 
(Fig. 3a,c). Along the same line, the R229Q podocin exerted a similar complementary effect on the 
localization of F344* podocin, indicating that missense podocin variants can block the internalization 
of coexpressed truncated podocin mutants. The effect of the C-terminal truncations on the podocin 
localization and the pathogenicity of different associations is summarized in Fig. 5. 
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Figure 5. Degree of oligomerization, localization and pathogenicity of truncated podocin 
associations. 
Both the wild type and R229Q oligomers (a) and the R286Tfs*17 monomers (b) are targeted to the 
plasma membrane. The pathogenic R229Q heterooligomers (here R229Q-F344Lfs*4) are localized in 
intracellular vesicles (c). Podocin variants lacking the region downstream to residue 343 are 
internalized (d), unless they heterodimerize with a membranous podocin variant with an intact C-
terminal tail (e).  
#predicted on an epidemiological basis, †predicted based on the localization of F344Lfs*4 podocin.  
wt podocin is shown in (light and dark) blue, R286Tfs*17 podocin in orange, R229Q podocin in 
purple, F344Lfs*4 in (dark and light) green 
nuc: nucleus, ER: endoplasmic reticulum, NS: nephrotic syndrome, ref: reference 
  
genotype
predicted	degree	of	
oligomerization
localization
(type	on	the	diagram)
clinical	
pathogenicity	(ref)
[wt];[wt] homooligomers membranous	(a) benign
[wt];[R229Q] heterooligomers membranous	(a) benign
[R229Q];[R229Q] homooligomers membranous	(a) benign	(18)
[R286Tfs*17];[R286Tfs*17] monomers membranous	(b)
intermediate-onset	
NS
[R286Tfs*17];[wt]
R286Tfs*17	monomer membranous	(b)
benign
wt oligomers membranous	(a)
[R286Tfs*17];[R229Q]
R286Tfs*17	monomer membranous	(b)
benign (29)
R229Q	oligomers membranous	(a)
[A317Lfs*31];[A317Lfs*31] homodimers partially	membranous early-onset	NS	(26)
[A317Lfs*31];[wt]
A317Lfs*31	homodimers partially	membranous
benignheterodimers partially	membranous
wt oligomers membranous (a)
[A317Lfs*31];[R229Q]
A317Lfs*31	homodimers partially	membranous
benign#heterodimers membranous
R229Q	oligomers membranous (a)
[F344Lfs*4];[F344Lfs*4] homooligomers internalized	(d) early-onset	NS†
[F344Lfs*4];[wt] heterooligomers membranous	(e) benign
[F344Lfs*4];[R229Q] heterooligomers
intracellular	
reticular/vesicular	(c)	
adult-onset	FSGS	
(20)
(a) (b)
(c)
(d)
(e)
Figure 5.	Degree of	oligomerization,	localization and	pathogenicity of	truncated podocin associations.
Both	the wild type and	R229Q	oligomers (a)	and	the R286Tfs*17	monomers (b)	are targeted to the plasma membrane.	The	pathogenic R229Q	heterooligomers
(here	R229Q-F344Lfs*4)	are localized in	intracellular vesicles (c).	Podocin variants lacking the region downstream to residue 343	are internalized (d),	unless they
heterodimerize with a	membranous podocin variant	with an	intact C-terminal tail (e).	
#predicted	on	an	epidemiological	basis,	†predicted	based	on	the	localization	of	F344Lfs*4	podocin.	
wt	podocin is	shown in	(light and	dark)	blue,	R286Tfs*17	podocin in	orange,	R229Q	podocin in	purple,	F344Lfs*4 in	(dark and	light)	green
nuc:	nucleus,	ER:	endoplasmic reticulum,	NS:	nephrotic	syndrome,	ref:	reference
nuc
ER
Golgi
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Discussion 
We formerly predicted that the C-terminal heterodimerization can mediate a dominant negative 
effect, and thus plays a key role in determining the pathogenicity of NPHS2 R229Q, the most 
common variant implicated in podocytopathies.19 Here we supply experimental data on the podocin 
dimerization, identify the oligomerization sites and present a novel mechanism through which 
coexpressed podocin variants can influence the localization of each other.  
We found podocin to oligomerize exclusively through the C-terminal tail, as the R286Tfs*17 podocin, 
with all three C-terminal helixes disrupted, is unable to dimerize, and, accordingly, does not 
colocalize through the trafficking with coexpressed podocin variants. This contrasts with the 
previously found capacity of the N-terminal region and the PHB domain to homodimerize, as shown 
by coimmunoprecipitation.8 This controversy is partially explained by our finding that the 270-286 
residues, belonging mainly to the PHB domain (124-282) and helical after the A272 residue can 
already mediate dimerization. We found the R286Tfs*17 to be a membranous and hypomorphic 
mutation, potentially explained by its intact PHB domain and thus reserved nephrin binding 
capacity.8 These results show that podocin dimerization is not necessary neither for membrane-
targeting, nor for a partial function. Stomatin oligomerization is similarly mediated by the C-terminal, 
but not by the N-terminal region 31,32, and is not prerequisite for membrane-targeting either.32 
Within the CTT, we found the oligomerization to be mediated by the 273-313 residues, 
corresponding primarily to the H1 domain and by the 332-348 residues, corresponding to the H2-H3 
linker and H3 helix. The H2 helix also influenced the dimerization though did not mediate it directly. 
In accordance with our previous molecular dynamics simulations,19,23 here we supplied experimental 
support for the coiled coil structure of the first oligomerization site by CD spectroscopy, providing the 
first direct data on the structure of a podocin fragment. These results are in perfect accordance with 
the organization of stomatin in homo-oligomeric complexes – comprising of 9- to 12-mers 31 – by the 
interaction of its coiled coil region,32 corresponding to H1 in podocin, and the 265_273STIVFPLPI 
residues,33 corresponding to the 336_344STVVLPLPF region of podocin. We found the podocin to 
Oligomerization mediates interactions of podocin 
 
 21 
oligomerize in vitro showing that raft-association is not necessary for its oligomerization. 
Furthermore, podocin fragments expressed in bacteria and in human cells produced a similar FRET 
efficiency, making it unlikely that eukaryote-specific post-translational modifications are required for 
oligomerization. 
Several observations demonstrate the causal relationship between oligomerization and interallelic 
interactions. We found the membrane localization of coexpressed podocin variants to strongly 
correlate only when the coexpressed podocin variants were able to dimerize. Furthermore, the H1, 
H2 and H3 regions correspond to the localization of the mutations that have been found pathogenic 
in trans with R229Q (H1: A284V, A288T, R291W, A297V, E310K, H2: L327F and Q328R, H3: 
F344Lfs*4).19 Finally, the FDL344_346LTY substitutions of F344Lfs*4 podocin exerted a dominant 
negative effect on R229Q podocin and changed in parallel the conformation of their heterodimer, as 
reflected by a decreased FRET efficiency.  
The oligomerization sites of podocin provide an explanation as to why the F344Lfs*4 podocin and not 
the R286Tfs*17 or A317Lfs*31 podocin mutants are pathogenic with R229Q even though all three 
affect oligomerization sites. The R286Tfs*17 podocin does not even dimerize with R229Q podocin. 
Though the A317Lfs*31 podocin binds it strongly and contains several substitutions that are known 
to induce formation of pathogenic oligomers with R229Q podocin (L327F or FDL344_346LTY), it lacks 
both the H2 and the second oligomerization site. The A317Lfs*31 podocin is thus expected to form 
only dimers, providing a potential explanation for its insufficient R229Q-retaining capacity.  
Besides the dominant negative effect, we found that oligomerization can mediate another type of 
interallelic interaction. In accordance with the results of Godel et al,24 who showed that a C-terminal 
truncation distal to the TVV337-339 motif leads to internalization, we found both the F344Lfs*4 and 
the F344* podocin mutants to be endocytosed. Their colocalization with internalized transferrin and 
partial membranous localization when coexpressed with the dominant negative mutant dynamin,34 
suggest that their endocytosis is clathrin-mediated, in accordance with recent data.35 Excitingly, 
these mutants became membranous when coexpressed with membranous podocin variants with an 
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intact CTT. As such, the coexpression of R238S podocin prevented the endocytosis of F344Lfs*4 
podocin providing the first example of a complementation between two pathogenic NPHS2 
mutations. It therefore seems to be sufficient for one component of the oligomer to contain an intact 
C-terminal to prevent endocytosis.  
It is tempting to speculate that the restored membrane localization of F344Lfs*4 podocin allows its 
partial functioning, in agreement with the hypomorphic nature of all membranous podocin mutants: 
the V180M, R238S or V290M podocin,30,36,37 or even the R286Tfs*17 podocin which lacks the whole 
CTT. Whether these hypomorphic mutations can entirely complement each other’s function remains 
to be determined. Interestingly, not a single patient compound heterozygous for them has ever been 
published.36,38 In accordance with the principal role of C-terminal oligomerization in the interallelic 
interactions, a de novo dominant NPHS2 mutation, segregating over three generations with the 
diseased phenotype (c.988_989delCT, p.L330Vfs*15) and affecting the second oligomerization site, 
has been recently published.39 This indicates that the wild type podocin can also be the subject of a 
dominant negative effect, as suggested by the reduced membrane targeting of wt podocin in the 
presence of A317Lfs*31 podocin in our experiments as well. These results emphasize that the 
interallelic interactions of NPHS2 are not restricted to the R229Q variant. Therefore, while evaluating 
the pathogenicity of 3’ NPHS2 mutations, interallelic interactions have to be taken into account. A C-
terminal truncating mutation is expected to exert a dominant negative effect if it does not disrupt 
the oligomerization, i.e. causes amino acid substitutions only in the second oligomerization site 
leading to a conformational rearrangement of the oligomer. Such an NPHS2 mutation leads to 
premature stop codon in the last exon and therefore does not result in nonsense-mediated RNA 
decay. The dominant negative effect is however also dependent on the trans-associated variant: 
while the L330Vfs*15 mutation is known to be pathogenic in trans with the wt allele, the F344Lfs*4 is 
only pathogenic with R229Q. Interallelic interactions influencing the degree of pathogenicity of trans-
associated pathogenic variants have been described in enzymopathies.40,41 The interactions of NPHS2 
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are nevertheless the first in an autosomal recessive disorder which act through the membrane-
trafficking and can invert the non-pathogenic nature of a variant. 
In conclusion, podocin oligomerization occurs through two C-terminal sites. Though it is not 
prerequisite for the membrane-localization, it can mediate interallelic interactions in several ways. In 
addition to the dominant negative effect, it can also result in complementation. These interactions 
therefore have to be considered while evaluating the pathogenicity of trans-associated 3’ NPHS2 
variants in compound heterozygous individuals.  
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Methods 
Generation of podocin-coding plasmids 
Human wild type podocin cDNA was amplified from the constructs described by Roselli et al 42 and 
subcloned into the BamHI/XhoI sites of LentiORF pLEX-MCS (Open Biosystems) or in frame with the 
Green Fluorescent Protein (GFP) cDNA into the XhoI/EcoRI sites of pEGFP-N1 (Clontech). The 
mutations R229Q, R238S, A297V, R286Tfs*17, A317Lfs*31, F344Lfs*4 and F344* were created using 
the QuickChange Site-directed Mutagenesis kit according to the manufacturer’s instructions 
(Agilent). Two copies of the hemagglutinin (HA) epitope tag were inserted by mutagenesis in the 
pLEX-MCS-podocin construct to express N-terminal HA-tagged proteins.  
For bacterial expression, the malE gene of pMAL-c2x and the GST gene of pGEX4T1 were cloned into 
the NdeI/BamHI sites of pET32b vector. The constructs encoding the 168-269, 168-286, 168-
R286Tfs*17, 168-292, 168-313, 168-331, 168-348 and 168-383 C-terminal fragments of podocin were 
subsequently cloned into the pET32b_MBP vector, the H1 fragment (272-313) into the pET32b_GST 
vector as an BamHI/XhoI DNA fragment. Constructs were verified by Sanger sequencing. 
 
Fluorescence Spectroscopy 
Podocin variants were expressed in HEK293 cells, cultured at 37°C in DMEM, high glucose with 10% 
FBS and 1% Penicillin-Streptomycin (Gibco, Thermo Fisher Scientific). Mycoplasma contamination 
was tested every month. Cells were transfected with vectors encoding HA-tagged podocin variants 
(CalPhos Mammalian Transfection Kit, Clontech). Transfected cells were incubated for 48 hours and 
lysed by 150 mM NaCl, 20 mM Tris, 1% Triton-X supplemented with 0.1% protease inhibitor 
(Protease Inhibitor Cocktail, Sigma Aldrich). Lysis and upcoming procedures were performed on ice. 
Lysates were incubated with monoclonal anti-HA antibodies (clone HA-7, Sigma Aldrich) and 
subsequently with Protein G magnetic beads (Dynabeads Protein G for Immunoprecipitation, Thermo 
Fisher Scientific). Immunprecipitates were washed three times with lysis buffer. Podocin variants 
were eluted by competition with HA peptides (HA Peptide lyophilized powder, Biotool), five times, 
Oligomerization mediates interactions of podocin 
 
 25 
each elution lasting at least 30 minutes. Concentration of the eluates was measured by 
spectrophotometry (DC Protein Assay, Bio-Rad). Eluates were verified by SDS-PAGE. Ten g protein 
was loaded on 4–20% MiniPROTEAN® TGX StainFree™ Protein Gel and transferred to a Trans-Blot® 
Turbo™ Mini Nitrocellulose membrane (Bio-Rad). Membranes were blocked with 5% nonfat dry milk 
in PBS and were incubated with anti-HA as primary (clone HA-7, Sigma Aldrich in PBS- 0.1% Tween 
20) and goat anti-mouse IgG-HRP as secondary antibodies (sc-2005, Santa Cruz Biotechnology). 
Proteins were visualized by chemiluminescence (Western Blotting Luminol Reagent, sc-2048, Santa 
Cruz Biotechnology) on Molecular Imager VersaDoc MP 5000 System (Bio-Rad). 
Protein aliquots (0.4 nmol) were stained separately with 4 nmol of either Alexa Fluor 488 C5 
Maleimide (donor dye) or Alexa Fluor 555 C2 Maleimide (acceptor dye) molecules (Invitrogen, 
Thermo Fisher Scientific) and were incubated overnight at 4°C. Differently stained podocin variants 
were subsequently mixed two by two for oligomerization, incubated for 2 hours on RT and washed 
through PD SpinTrap G-25 filter column (GE Healthcare Sciences) to discard the unbound HA peptides 
and fluorophores. Förster type Resonance Energy Transfer (FRET) was measured between two 
differently stained podocin variants in a final volume of 100 l, containing each podocin with a 
concentration of 4 M. The fluorescence lifetime of the donor dye (Alexa 488 C5) was measured with 
a Chronos BH Time Correlated Single Photon Counting lifetime spectrometer (ISS Inc., Champaign, IL) 
using an excitation wavelength of 488 nm with a 3 nm band pass and an emission wavelength of 524 
nm with a 5 nm band pass. A pulsed excitation of 0.8 ns full width at half maximum was used and 3 x 
108 pulses were integrated for each lifetime measurement. The fluorescence lifetime was 
determined by an iterative re-convolution procedure employing least-squares fitting using the Vinci2 
software (ISS Inc). Every iterative re-convolution was repeated at least three times with different 
starting parameters set to ensure correct convergence of the fitting parameters. The lifetime was 
determined both by multi-exponential fitting, and by lifetime distribution fitting. The variance (Var) 
of the lifetime values was determined from the nonlinear least squares algorithm by 𝑉𝑎𝑟(𝜏) =  𝜎2 ∙
∇f(τ) ∗ ∇f(τ)𝑇 where  is the fitted lifetime parameter set, ∇f is the gradient vector of the fitting 
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function, and σ2 is the chi-square error value. The FRET efficiency is computed as 𝐹𝑅𝐸𝑇 = 1 −
𝜏𝑠𝑎𝑚𝑝𝑙𝑒
𝜏𝑑𝑜𝑛𝑜𝑟
 
where sample is the donor dye lifetime in the donor-acceptor pair sample, and donor is the donor dye 
lifetime without acceptor present. The standard deviation of the FRET values was determined from 
the variances by the Taylor-expansion method according to the equation: Var(FRET) =
Var(τdonor) ∙ (
𝜕𝐹𝑅𝐸𝑇
𝜕𝜏𝑑𝑜𝑛𝑜𝑟
)
2
+ 𝑉𝑎𝑟(𝜏𝑠𝑎𝑚𝑝𝑙𝑒) ∙ (
𝜕𝐹𝑅𝐸𝑇
𝜕𝜏𝑠𝑎𝑚𝑝𝑙𝑒
)
2
. Experiments were repeated three times on 
samples obtained from at least two different expressions. The FRET efficiency values were averaged, 
and the standard deviation was calculated according to the summation rule of the variances 
assuming the independency of the measurements. 
 
Expression and purification of podocin fragments in E. coli 
Bacteria (E. coli strain BL21-DE3) were transformed and grown at 37°C in LB media supplemented 
with 100 µg/ml ampicillin and 2 g glucose to the OD600 of 0.8. To induce protein expression, 0.25 
mM isopropyl b-D-1-thiogalactopyranoside (IPTG) was added. After 18 hours of incubation at 16°C, 
cells were harvested by centrifugation (4500 x g, 20 min, 4°C). 
Pelleted cells containing the GST-fused H1-fragment were resuspended in buffer A (50 mM Tris, 150 
mM NaCl, 1 mM EDTA, pH 7.5) and lysed by sonication. The lysate was clarified by centrifugation 
(23000 x g, 20 min, 4°C). The supernatant was applied to a gravity column with 2 ml GST resin 
(Macherey-Nagel), pre-equilibrated and washed with buffer A, eluted with buffer B1 (50 mM Tris, 
150 mM NaCl, pH 8.0). The eluted protein was dialyzed against buffer C1 (50 mM Tris, 150 mM NaCl, 
20mM GSH, pH 8.0) and cleaved by thrombin. The GST was separated from the peptides by a 
subsequent GST purification step. The H1 fragments were further purified by reverse-phase HPLC on 
a C-18 (Phenomenex) column by using a gradient of water/acetonitrile. Collected fractions were 
lyophilized and their identity was confirmed by using a Perkin–Elmer Sciex API2000 mass 
spectrometer. 
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Cell pellets containing the MBP-fused podocin fragments were lysed and clarified as described above. 
The supernatant was applied to a gravity column with 5 ml amylose resin pre-equilibrated and 
washed with buffer A, eluted with buffer B2 (50 mM Tris, 150 mM NaCl, 40 mM Maltose, pH 7.5). 
The eluted protein was dialysed against buffer C2 (50mM Tris, 50 mM NaCl, 1 mM DTT, pH 7.5) and 
subsequently an Q-IEX purification was performed by using a gradient of buffer D2 (50 mM Tris, 1 M 
NaCl, 1 mM DTT, pH 7.5). The eluted fraction was purified and subsequently analyzed by gel-filtration 
chromatography using buffer A (50 mM Tris, 50 mM NaCl, pH 7.5) with 10 μM of protein in buffer A. 
These purified MBP-fused podocin fragments were used to perform FRET experiments with 40 μM of 
protein in buffer A. Maleimide staining and FRET measurements were performed as described above. 
 
Electronic Circular Dichroism Spectroscopy 
Far-UV ECD spectra were recorded on a Jasco J810 spectrophotometer using cuvettes with a path 
length of 1.0 mm with protein concentrations of 40 μM. Typical spectral accumulation parameters 
were a scan rate of 50 nm/min with a 1 nm bandwidth and a 0.2 nm step resolution over wavelength 
ranges of 185–260 nm (far-UV) with four scans averaged for each spectrum. The temperature at the 
cell was controlled by a Peltier-type heating system. The solvent reference spectra were used as 
baselines that were automatically subtracted from the peptide spectra. The raw ellipticity data were 
converted into mean residue molar ellipticity units ([Θ]MR, degrees square centimeters per decimole). 
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Expression of podocin variants in podocytes 
A human immortalized podocyte cell line (AB8/13) provided by M. Saleem (University of Bristol, UK) 
43 was cultured at 33°C in RPMI-1640 supplemented with 10% FBS, insulin-transferrin-selenium (Life 
Technologies), and 50 IU/ml penicillin/streptomycin (Life Technologies). The podocytes do not 
express endogenous podocin and remain undifferentiated at this growth-permissive temperature 43. 
Cells were tested for mycoplasma contamination every 3 months. Podocytes were cultured on type I 
collagen-coated coverslips and cotransfected with plasmids encoding HA-podocin or podocin-GFP 
variants using FuGENE HD according to the manufacturer’s instructions (Promega). To assess the 
colocalization of podocin and internalized transferrin, podocytes were washed after 24 hrs of 
transfection, and pre-incubated with serum-free and insulin-transferrin-selenium free RPMI-1640 for 
1 hr at 33°C. Then, cells were incubated with 8 μg/ml of Alexa594-conjugated transferrin (Life 
Technologies), in serum-free medium for 1 hr at 4°C. Cells were washed with PBS, then placed at 
33°C for 10 min to let the transferrin internalize, washed with PBS twice and fixed in 4% 
formaldehyde. After washing, cells were treated with 50 mM NH4Cl and incubated with a blocking 
solution (PBS, 1% BSA, 0.1% Tween20) for 1 hr prior to primary antibody hybridization then with 
appropriate Alexa Fluor-conjugated secondary antibodies (Life Technologies). Nuclei were stained 
with Hoechst (Life Technologies). To assess the effect of dynamin on HA-podocin variants 
internalization, GFP-fused wild-type or dominant negative mutant (K44A) dynamin 27 was co-
expressed with HA-podocin variants in podocytes. 
 
Analysis of the subcellular localization of podocin 
Transfected podocytes were incubated with Alexa Fluor 555-conjugated wheat germ agglutinin 
(WGA; Life technologies) for 20 min at 4°C to stain plasma membrane, then fixed with ice-cold 
ethanol for 5 min. Fixed cells were blocked with PBS/BSA 1% for 15 min and incubated with mouse 
anti-HA primary antibodies (Covance) followed by Alexa Fluor 647-conjugated secondary antibodies 
(Life technologies). Confocal optical slices were captured using a 40x oil objective lens (Leica 
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Microsystems), an optical slice thickness of 800 nm, a Z-step size of 250 nm and XY pixel size of 86 
nm (Leica SP8 confocal microscope, Necker Imaging Facility). The perimembranous region was 
defined by delimitating WGA-labeled membrane extensions using ImageJ 1.51k software. The 
membrane-targeting of podocin proteins was characterized by the ratio of the WGA-labeled 
perimembranous area which colocalized with podocin, and was quantified as the Manders' 
coefficient, calculated by ImageJ.  
 
Statistical analysis 
FRET efficiencies were compared by ANOVA and Tukey HSD post-hoc test. The fraction of plasma 
membrane overlapping podocin was compared using Kruskal-Wallis test followed, if significant, by 
Multiple comparisons of mean ranks. Renal survival in patients with R286Tfs*17 and A317Lfs*31 
mutations was compared by log-rank test. The effect of dynamin on the membrane localization of 
podocin variants was assessed by Mann-Whitney U test. Correlation between the membrane 
localization of coexpressed podocin variants was tested by Pearson correlation. All statistical analyses 
were performed by Statistica software version 13.2. 
 
Disclosure  
The authors declare no competing financial interest. 
  
Oligomerization mediates interactions of podocin 
 
 30 
References 
1. Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is 
mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 
2000;24(4):349-354. 
2. Machuca E, Benoit G, Nevo F, et al. Genotype-phenotype correlations in non-Finnish 
congenital nephrotic syndrome. J Am Soc Nephrol. 2010;21(7):1209-1217. 
3. Hinkes BG, Mucha B, Vlangos CN, et al. Nephrotic syndrome in the first year of life: two thirds 
of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics. 
2007;119(4):e907-919. 
4. Santin S, Bullich G, Tazon-Vega B, et al. Clinical Utility of Genetic Testing in Children and 
Adults with Steroid-Resistant Nephrotic Syndrome. Clin J Am Soc Nephrol. 2011. 
5. Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-
resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279-1289. 
6. Schwarz K, Simons M, Reiser J, et al. Podocin, a raft-associated component of the glomerular 
slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest. 2001;108(11):1621-1629. 
7. Roselli S, Gribouval O, Boute N, et al. Podocin localizes in the kidney to the slit diaphragm 
area. Am J Pathol. 2002;160(1):131-139. 
8. Huber TB, Simons M, Hartleben B, et al. Molecular basis of the functional podocin-nephrin 
complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. 
Hum Mol Genet. 2003;12(24):3397-3405. 
9. Huber TB, Kottgen M, Schilling B, Walz G, Benzing T. Interaction with podocin facilitates 
nephrin signaling. J Biol Chem. 2001;276(45):41543-41546. 
10. Tossidou I, Teng B, Drobot L, et al. CIN85/RukL is a novel binding partner of nephrin and 
podocin and mediates slit diaphragm turnover in podocytes. J Biol Chem. 
2010;285(33):25285-25295. 
11. Kim EY, Anderson M, Wilson C, Hagmann H, Benzing T, Dryer SE. NOX2 interacts with 
podocyte TRPC6 channels and contributes to their activation by diacylglycerol: essential role 
of podocin in formation of this complex. Am J Physiol Cell Physiol. 2013;305(9):C960-971. 
12. Huber TB, Schermer B, Muller RU, et al. Podocin and MEC-2 bind cholesterol to regulate the 
activity of associated ion channels. Proc Natl Acad Sci U S A. 2006;103(46):17079-17086. 
13. Reiser J, Polu KR, Moller CC, et al. TRPC6 is a glomerular slit diaphragm-associated channel 
required for normal renal function. Nat Genet. 2005;37(7):739-744. 
14. Exome Variant Server NGESPE. Seattle, WA (URL: http://evs.gs.washington.edu/EVS/). 
15. Tsukaguchi H, Sudhakar A, Le TC, et al. NPHS2 mutations in late-onset focal segmental 
glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest. 
2002;110(11):1659-1666. 
16. Tonna S, Wang YY, Wilson D, et al. The R229Q mutation in NPHS2 may predispose to 
proteinuria in thin-basement-membrane nephropathy. Pediatr Nephrol. 2008;23(12):2201-
2207. 
17. Voskarides K, Arsali M, Athanasiou Y, Elia A, Pierides A, Deltas C. Evidence that NPHS2-R229Q 
predisposes to proteinuria and renal failure in familial hematuria. Pediatr Nephrol. 
2012;27(4):675-679. 
18. Kerti A, Csohany R, Wagner L, Javorszky E, Maka E, Tory K. NPHS2 homozygous p.R229Q 
variant: potential modifier instead of causal effect in focal segmental glomerulosclerosis. 
Pediatr Nephrol. 2013;28(10):2061-2064. 
19. Tory K, Menyhard DK, Woerner S, et al. Mutation-dependent recessive inheritance of NPHS2-
associated steroid-resistant nephrotic syndrome. Nat Genet. 2014;46(3):299-304. 
20. Lipska BS, Balasz-Chmielewska I, Morzuch L, et al. Mutational analysis in podocin-associated 
hereditary nephrotic syndrome in Polish patients: founder effect in the Kashubian 
population. J Appl Genet. 2013;54(3):327-333. 
Oligomerization mediates interactions of podocin 
 
 31 
21. Dosztanyi Z, Csizmok V, Tompa P, Simon I. IUPred: web server for the prediction of 
intrinsically unstructured regions of proteins based on estimated energy content. 
Bioinformatics. 2005;21(16):3433-3434. 
22. Drozdetskiy A, Cole C, Procter J, Barton GJ. JPred4: a protein secondary structure prediction 
server. Nucleic Acids Res. 2015;43(W1):W389-394. 
23. Yokoyama H, Fujii S, Matsui I. Crystal structure of a core domain of stomatin from Pyrococcus 
horikoshii Illustrates a novel trimeric and coiled-coil fold. J Mol Biol. 2008;376(3):868-878. 
24. Godel M, Ostendorf BN, Baumer J, Weber K, Huber TB. A novel domain regulating 
degradation of the glomerular slit diaphragm protein podocin in cell culture systems. PLoS 
One. 2013;8(2):e57078. 
25. Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. Nat 
Protoc. 2006;1(6):2876-2890. 
26. Hinkes B, Vlangos C, Heeringa S, et al. Specific podocin mutations correlate with age of onset 
in steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2008;19(2):365-371. 
27. van der Bliek AM, Redelmeier TE, Damke H, Tisdale EJ, Meyerowitz EM, Schmid SL. Mutations 
in human dynamin block an intermediate stage in coated vesicle formation. J Cell Biol. 
1993;122(3):553-563. 
28. McCarthy HJ, Bierzynska A, Wherlock M, et al. Simultaneous sequencing of 24 genes 
associated with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2013;8(4):637-
648. 
29. He N, Zahirieh A, Mei Y, et al. Recessive NPHS2 (Podocin) mutations are rare in adult-onset 
idiopathic focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2(1):31-37. 
30. Roselli S, Moutkine I, Gribouval O, Benmerah A, Antignac C. Plasma membrane targeting of 
podocin through the classical exocytic pathway: effect of NPHS2 mutations. Traffic. 
2004;5(1):37-44. 
31. Snyers L, Umlauf E, Prohaska R. Oligomeric nature of the integral membrane protein 
stomatin. J Biol Chem. 1998;273(27):17221-17226. 
32. Rungaldier S, Umlauf E, Mairhofer M, Salzer U, Thiele C, Prohaska R. Structure-function 
analysis of human stomatin: A mutation study. PLoS One. 2017;12(6):e0178646. 
33. Umlauf E, Mairhofer M, Prohaska R. Characterization of the stomatin domain involved in 
homo-oligomerization and lipid raft association. J Biol Chem. 2006;281(33):23349-23356. 
34. Lee A, Frank DW, Marks MS, Lemmon MA. Dominant-negative inhibition of receptor-
mediated endocytosis by a dynamin-1 mutant with a defective pleckstrin homology domain. 
Curr Biol. 1999;9(5):261-264. 
35. Sasaki Y, Hidaka T, Ueno T, et al. Sorting Nexin 9 facilitates podocin endocytosis in the injured 
podocyte. Sci Rep. 2017;7:43921. 
36. Kerti A, Csohany R, Szabo A, et al. NPHS2 p.V290M mutation in late-onset steroid-resistant 
nephrotic syndrome. Pediatr Nephrol. 2012. 
37. Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic 
heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. 
Kidney Int. 2004;66(2):571-579. 
38. Bouchireb K, Boyer O, Gribouval O, et al. NPHS2 mutations in steroid-resistant nephrotic 
syndrome: a mutation update and the associated phenotypic spectrum. Hum Mutat. 
2014;35(2):178-186. 
39. Suvanto M, Patrakka J, Jahnukainen T, et al. Novel NPHS2 variant in patients with familial 
steroid-resistant nephrotic syndrome with early onset, slow progression and dominant 
inheritance pattern. Clin Exp Nephrol. 2016. 
40. Shen N, Heintz C, Thiel C, Okun JG, Hoffmann GF, Blau N. Co-expression of phenylalanine 
hydroxylase variants and effects of interallelic complementation on in vitro enzyme activity 
and genotype-phenotype correlation. Mol Genet Metab. 2016;117(3):328-335. 
Oligomerization mediates interactions of podocin 
 
 32 
41. Rodriguez-Pombo P, Perez-Cerda C, Perez B, Desviat LR, Sanchez-Pulido L, Ugarte M. Towards 
a model to explain the intragenic complementation in the heteromultimeric protein 
propionyl-CoA carboxylase. Biochim Biophys Acta. 2005;1740(3):489-498. 
42. Kitamura A, Tsukaguchi H, Maruyama K, et al. Steroid-resistant nephrotic syndrome. Kidney 
Int. 2008;74(9):1209-1215. 
43. Saleem MA, O'Hare MJ, Reiser J, et al. A conditionally immortalized human podocyte cell line 
demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002;13(3):630-638. 
  
Oligomerization mediates interactions of podocin 
 
 33 
Acknowledgements 
We thank Mária Bernáth for the technical assistance. We greatly acknowledge Meriem Garfa-Traoré 
and Nicolas Goudin of the Cell Imaging Platform at Imagine Institute for providing expert knowledge 
on confocal microscopy. Human immortalized podocytes were kindly provided by M. Saleem (Bristol 
Royal Hospital for Children, University of Bristol, UK). Financial support for this work was provided by 
MTA-SE Lendulet Research Grant (LP2015-11/2015) of the Hungarian Academy of Sciences, 
NKFIA/OTKA K109718, K116305, KH125566, MedinProt Synergy grant (DKM, SP and TK), State 
funding from the Agence Nationale de la Recherche under "Investissements d'avenir" program (ANR-
10-IAHU-01), EURenOmics (the European Community’s 7th Framework program grant 2012-305608), 
the Agence Nationale de la Recherche (GenPod project ANR-12-BSV1-0033.01), Eotvos Scholarship of 
the Hungarian State (KT) and by the French-Hungarian bilateral project (PHC 34501SM Balaton, 
Hungarian Grant No. TeT_14_1-2015-0020). 
 
Author contributions 
KT, GM, PS, GS, CAn, DKM, AB, AP designed the study. CAr performed the mutagenesis and 
the expression experiments in podocytes. KT analyzed the membrane targeting of podocin. PS 
performed the bacterial expressions, ECD spectroscopy measurements and the size exclusion 
chromatography experiments. EB and AM produced the podocin variants for FRET measurements. GS 
and GL performed the FRET experiments. KT and GS made the statistical analyses. KT, GS, DKM, PS, 
EB and GM wrote the paper.  
